Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects.

6 In another RCT conducted in Hong Kong, China, IFN-α also showed a trend to prolong the survival time of patients with HBV-related HCC after surgery. 21 In a meta-analysis of 9 RCTs and 5 cohort studies, IFN was found to decrease the mortality and recurrence rates in HCV-related HCC, and to decrease mortality but not reduce the recurrence rate in HBV-related HCC. 22 A s

also in 53,322 other papers

Chemotherapy and radiotherapy In contrast to other solid malignancies, chemotherapy plays a limited role in the treatment of advanced HCC, except that oxaliplatin plus fluorouracil/leucovorin (FOLFOX4 regimen) was found to prolong patient survival with borderline significance compared with doxorubicin. 45 As summarized in Table 1 , chemotherapy with capecitabine, tegafur/uracil, or epirubicin plus carmofur were investigated as adjuvant treatment; however, all of them failed to prolong patient survival and only capecitabine was found to prolong patient RFS.

also in 7,017 other papers